In the Canadian pharmaceutical industry, there were 19 M&A deals announced in Q2 2023, worth a total value of $2.1bn, according to GlobalData’s Deals Database. The $2bn acquisition of bellus health by gsk was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes, the M&A activity and most notable deals are included in GlobalData’s Pharma Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, M&A activity in Canada increased by 6187% in Q2 2023 compared with the previous quarter’s total of $33.4m and fell by 8% as compared to Q2 2022. Related deal volume increased by 46% in Q2 2023 versus the previous quarter and was 36% higher than in Q2 2022.
The top-ranked financial advisors supporting these M&A deals in Canada in Q2 2023 were Centerview Partners; FOS Advisors; NG Holdings Canada with 1, 1, 1 deals respectively.
The top-ranked legal advisorss supporting these M&A deals in Canada Q2 2023 were Fasken Martineau DuMoulin; Morgan, Lewis & Bockius; Stikeman Elliott with 4, 3, 3 deals respectively.
For further understanding of GlobalData's Pharma Industry Mergers and Acquisitions Deals by Top Themes, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.